Video

Dr. Morris on the Role of Circulating Tumor DNA in Resected Colon Cancer

Van K. Morris, MD, discusses the role of circulating tumor DNA in resected colon cancer.

Van K. Morris, MD, assistant professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discusses the role of circulating tumor DNA (ctDNA) in resected colon cancer.

Regardless of stage, patients with colon cancer who have detectable ctDNA following surgery are at a higher risk of recurrence compared with those who have undetectable ctDNA after resection, explains Morris.

The presence of ctDNA in colon cancer serves as a surrogate for the presence of microscopic minimal residual disease, Morris says. Moreover, ctDNA has been shown to be a valid prognostic biomarker to stratify patients by their risk of recurrence.

However, utilizing ctDNA as a predictive biomarker to determine whether a patient is likely to respond to chemotherapy requires further research, concludes Morris.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity